Skip to main content

Retinitis Pigmentosa clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Showing trials for
  • RTx-015 Injection in Retinitis Pigmentosa Patients

    Sorry, not yet accepting patients

    A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 9 eligible patients with retinitis pigmentosa will be enrolled sequentially in up to 3 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 12 months.

    Orange, California and other locations

Last updated: